Understanding CJC-1295 with DAC vs without DAC helps researchers compare these two peptide forms. CJC-1295 with DAC and CJC-1295 without DAC are two forms of the same growth hormone-releasing hormone (GHRH) analogue, and the difference between them shapes how researchers design their protocols. Both molecules stimulate the pituitary gland, but a small structural addition changes how long each version stays active in circulation. Understanding this distinction helps laboratories select the right compound for their study goals.
What Is CJC-1295?
CJC-1295 is a synthetic peptide modeled on the first 29 amino acids of endogenous GHRH. This fragment, known as GRF(1-29), is the shortest sequence that retains full growth hormone-releasing activity. Researchers modified the native sequence at several positions to resist enzymatic breakdown. The result is a more stable analogue that binds GHRH receptors on the anterior pituitary and prompts pulsatile growth hormone release.
The core peptide is often paired with a growth hormone secretagogue such as Ipamorelin in research models. GHRH analogues and secretagogues act on different receptors, so investigators frequently study them together to observe combined signaling effects.
The Role of DAC (Drug Affinity Complex)
DAC stands for Drug Affinity Complex, a maleimidopropionic acid group attached to the peptide. Once introduced, this group binds covalently to circulating albumin. Albumin is an abundant blood protein with a long half-life, so tethering the peptide to it dramatically slows clearance. This is the single feature that separates the two versions of CJC-1295.
Without DAC, the peptide is essentially stabilized GRF(1-29), sometimes labeled Mod GRF 1-29. It lacks the albumin-binding group, so it circulates only briefly before enzymes clear it.
Half-Life and Release Profile
The half-life gap is the most studied contrast between these compounds. CJC-1295 with DAC has a reported half-life of roughly six to eight days, producing a sustained elevation in growth hormone and IGF-1 sometimes called a “GH bleed.” CJC-1295 without DAC clears within about 30 minutes, generating a sharp, short pulse that more closely mimics natural GHRH rhythm.
This difference guides experimental design. Studies focused on steady, prolonged receptor exposure often use the DAC version. Studies aiming to replicate physiological pulsatility, or to pair timed pulses with a secretagogue, typically favor the CJC-1295 no DAC form.
Choosing Between CJC-1295 With DAC vs Without DAC in Research
Neither version is universally superior; the choice depends on the research question. The DAC form reduces dosing frequency and holds growth hormone signaling elevated over long windows, which suits chronic-exposure models. The no-DAC form offers tight temporal control and a pulsatile pattern that researchers value when studying receptor sensitivity or natural secretion mimicry.
Purity and consistent reconstitution matter for both. Small differences in peptide handling can affect the reproducibility of half-life and signaling observations, so careful laboratory technique remains essential.
Key Takeaways
The takeaway is straightforward. Both compounds are GHRH analogues built on GRF(1-29). The DAC version binds albumin for a multi-day half-life and sustained signaling, while the no-DAC version clears in minutes for a natural pulse. Matching the compound to the study design is the core decision researchers face.
All products sold at EhBuddy Peptides are for laboratory and scientific research purposes only and are not intended for human or veterinary administration. EhBuddy Peptides ships all orders from within Canada.
For published scientific context, researchers can review related literature on PubMed. All products are for laboratory research use only and ship from Canada.
